GCCL, Medicover Sign MOU for Clinical Trial Services Expansion

GCCL Co., Ltd. (GCCL) and Medicover Integrated Clinical Services (MICS), a division of Medicover, have entered into a Memorandum of Understanding (MOU) aimed at advancing multinational clinical trial services. The agreement brings together GCCL, a data-driven clinical trial services provider, and MICS, which operates under Medicover, an international healthcare and diagnostic services company, to formalize cooperation across multiple global regions.

Under the terms of the MOU, the two organizations intend to build a coordinated framework spanning Europe, the United States, and the Asia-Pacific (APAC) region. Drawing on their respective strengths in clinical trial operations and client communications across these key markets, the collaboration is designed to improve cross-regional communication efficiency while reinforcing operational stability in global clinical trial projects.

The scope of cooperation outlined in the agreement is broad. Key areas of collaboration under the MOU include clinical trial operations and sample analysis collaboration across regions; project management support and coordinated client communication by region; joint marketing collaboration; joint client development and market expansion; and the enhancement of service competitiveness through test item alignment and improved analytical efficiency. Together, these initiatives are intended to streamline processes and align service delivery standards across continents.

The partnership structure leverages complementary capabilities. MICS contributes its extensive experience and established network in Europe and the U.S., while GCCL brings specialized analytical capabilities and project management expertise in the APAC region. By integrating these strengths, both parties expect to create a more seamlessly connected and optimized environment for multinational clinical trial operations and analysis.

“This agreement represents an important opportunity to effectively combine the expertise and customer bases of both organizations and further strengthen the global clinical trial ecosystem,” said Łukasz Hubisz, General Manager of MICS. “Through our collaboration with GCCL, we aim to strengthen communication with clients in Asia and support the smoother execution of global clinical trial projects.”

Kwan Goo Cho, CEO of GCCL, added, “This partnership marks an important first step in reinforcing clinical collaboration between Europe and Asia. Through our strategic cooperation with MICS, we aim to set new standards for global clinical trial execution and deliver meaningful analytical outcomes for our clients.”